Faecal Calprotectin Testing Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Description
Market Overview:
The Faecal Calprotectin Testing Market is expected to grow from USD 201,112 million in 2024 to USD 332,839.48 million by 2032, representing a compound annual growth rate (CAGR) of 6.5%.
This growth is driven by the increasing prevalence of gastrointestinal diseases such as inflammatory bowel disease (IBD) and colorectal cancer, where early detection significantly improves patient outcomes. The growing preference for non-invasive diagnostic methods and the rising demand for personalized healthcare further contribute to market expansion. Technological advancements have enhanced testing methods, making faecal calprotectin testing a preferred diagnostic tool due to its accuracy and efficiency. Additionally, the expanding geriatric population, combined with a stronger focus on early diagnosis and preventive healthcare, is fostering market growth. The integration of faecal calprotectin testing with digital health solutions is enabling improved disease monitoring and management. Increased healthcare investments in emerging markets and partnerships among diagnostic companies are also expected to accelerate market adoption, strengthening overall market dynamics in the years ahead.
Market Drivers:
Non-Invasive Diagnostic Methods:
As healthcare providers and patients prioritize non-invasive diagnostic options, faecal calprotectin testing has gained popularity due to its ability to accurately assess gastrointestinal inflammation without invasive procedures like colonoscopies. For example, Calpro AS offers non-invasive faecal calprotectin test kits that are widely used to assess gastrointestinal inflammation. The preference for non-invasive testing is driven by convenience, reduced risks, and lower patient discomfort, making faecal calprotectin a more appealing option. As more individuals seek reliable, efficient, and minimally disruptive disease detection methods, the adoption of faecal calprotectin testing continues to grow.
Market Challenges:
High Cost of Testing:
A significant challenge in the faecal calprotectin testing market is the high cost associated with these tests, which can limit accessibility, particularly in developing regions. Testing kits, laboratory processing, and necessary follow-up consultations can create a financial burden for both healthcare providers and patients. This is especially problematic in regions with limited healthcare resources or in countries where diagnostic tests are not fully reimbursed by the healthcare system. Although faecal calprotectin testing plays a crucial role in early detection and monitoring of gastrointestinal diseases, its high cost remains a barrier to widespread adoption. Healthcare providers may be hesitant to incorporate these tests into routine practice, which could hinder market growth. Additionally, the need for specialized equipment and trained personnel further increases the expenses, creating challenges for implementation in low-resource settings.
Market Segmentation:
By Assay:
Enzyme-linked Immunosorbent Assay (ELISA)
Enzyme Fluoroimmunoassay
Quantitative Immunochromatography
By Application:
Inflammatory Bowel Disease (IBD)
Colorectal Cancer
Others
By End-Use:
Hospitals and Clinics
Diagnostic Laboratories
Academic and Research Institutes
By Geography:
North America:
U.S.
Canada
Mexico
Europe:
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific:
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America:
Brazil
Argentina
Rest of Latin America
Middle East & Africa:
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Players:
Eagle Biosciences, Inc.
Actim
DRG International Inc.
Svar Life Science
ALPCO
Epitope Diagnostics Inc.
OPERON
BÜHLMANN
Hycult Biotech
Diazyme Laboratories
The Faecal Calprotectin Testing Market is expected to grow from USD 201,112 million in 2024 to USD 332,839.48 million by 2032, representing a compound annual growth rate (CAGR) of 6.5%.
This growth is driven by the increasing prevalence of gastrointestinal diseases such as inflammatory bowel disease (IBD) and colorectal cancer, where early detection significantly improves patient outcomes. The growing preference for non-invasive diagnostic methods and the rising demand for personalized healthcare further contribute to market expansion. Technological advancements have enhanced testing methods, making faecal calprotectin testing a preferred diagnostic tool due to its accuracy and efficiency. Additionally, the expanding geriatric population, combined with a stronger focus on early diagnosis and preventive healthcare, is fostering market growth. The integration of faecal calprotectin testing with digital health solutions is enabling improved disease monitoring and management. Increased healthcare investments in emerging markets and partnerships among diagnostic companies are also expected to accelerate market adoption, strengthening overall market dynamics in the years ahead.
Market Drivers:
Non-Invasive Diagnostic Methods:
As healthcare providers and patients prioritize non-invasive diagnostic options, faecal calprotectin testing has gained popularity due to its ability to accurately assess gastrointestinal inflammation without invasive procedures like colonoscopies. For example, Calpro AS offers non-invasive faecal calprotectin test kits that are widely used to assess gastrointestinal inflammation. The preference for non-invasive testing is driven by convenience, reduced risks, and lower patient discomfort, making faecal calprotectin a more appealing option. As more individuals seek reliable, efficient, and minimally disruptive disease detection methods, the adoption of faecal calprotectin testing continues to grow.
Market Challenges:
High Cost of Testing:
A significant challenge in the faecal calprotectin testing market is the high cost associated with these tests, which can limit accessibility, particularly in developing regions. Testing kits, laboratory processing, and necessary follow-up consultations can create a financial burden for both healthcare providers and patients. This is especially problematic in regions with limited healthcare resources or in countries where diagnostic tests are not fully reimbursed by the healthcare system. Although faecal calprotectin testing plays a crucial role in early detection and monitoring of gastrointestinal diseases, its high cost remains a barrier to widespread adoption. Healthcare providers may be hesitant to incorporate these tests into routine practice, which could hinder market growth. Additionally, the need for specialized equipment and trained personnel further increases the expenses, creating challenges for implementation in low-resource settings.
Market Segmentation:
By Assay:
Enzyme-linked Immunosorbent Assay (ELISA)
Enzyme Fluoroimmunoassay
Quantitative Immunochromatography
By Application:
Inflammatory Bowel Disease (IBD)
Colorectal Cancer
Others
By End-Use:
Hospitals and Clinics
Diagnostic Laboratories
Academic and Research Institutes
By Geography:
North America:
U.S.
Canada
Mexico
Europe:
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific:
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America:
Brazil
Argentina
Rest of Latin America
Middle East & Africa:
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Players:
Eagle Biosciences, Inc.
Actim
DRG International Inc.
Svar Life Science
ALPCO
Epitope Diagnostics Inc.
OPERON
BÜHLMANN
Hycult Biotech
Diazyme Laboratories
Table of Contents
196 Pages
- CHAPTER NO. 1 : INTRODUCTION
- 1.1.1. Report Description
- Purpose of the Report
- USP & Key Offerings
- 1.1.2. Key Benefits for Stakeholders
- 1.1.3. Target Audience
- 1.1.4. Report Scope
- CHAPTER NO. 2 : EXECUTIVE SUMMARY
- 2.1. Faecal Calprotectin Testing Market Snapshot
- 2.1.1. Faecal Calprotectin Testing Market, 2018 - 2032 (USD Million)
- CHAPTER NO. 3 : Faecal Calprotectin Testing Market – INDUSTRY ANALYSIS
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Market Opportunities
- 3.5. Porter’s Five Forces Analysis
- CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE
- 4.1. Company Market Share Analysis – 2023
- 4.2. Faecal Calprotectin Testing Market Company Revenue Market Share, 2023
- 4.3. Company Assessment Metrics, 2023
- 4.4. Start-ups /SMEs Assessment Metrics, 2023
- 4.5. Strategic Developments
- 4.6. Key Players Product Matrix
- CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS
- CHAPTER NO. 6 : Faecal Calprotectin Testing Market – BY Based on Assay: ANALYSIS
- CHAPTER NO. 7 : Faecal Calprotectin Testing Market – BY Based on Application: ANALYSIS
- CHAPTER NO. 8 : Faecal Calprotectin Testing Market – BY Based on End-use: ANALYSIS
- CHAPTER NO. 9 : Faecal Calprotectin Testing Market – BY Based on the Geography: ANALYSIS
- CHAPTER NO. 10 : COMPANY PROFILES
- 9.1. Eagle Biosciences, Inc.
- 9.1.1. Company Overview
- 9.1.2. Product Portfolio
- 9.1.3. SWOT Analysis
- 9.1.4. Business Strategy
- 9.1.5. Financial Overview
- 9.2. Actim
- 9.3. DRG International Inc.
- 9.4. Svar Life Science
- 9.5. ALPCO
- 9.6. Epitope Diagnostics Inc.
- 9.7. OPERON
- 9.8. BÜHLMANN
- 9.9. Hycult Biotech
- 9.10. Diazyme Laboratories
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
